BR9611861A - Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc - Google Patents

Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc

Info

Publication number
BR9611861A
BR9611861A BR9611861A BR9611861A BR9611861A BR 9611861 A BR9611861 A BR 9611861A BR 9611861 A BR9611861 A BR 9611861A BR 9611861 A BR9611861 A BR 9611861A BR 9611861 A BR9611861 A BR 9611861A
Authority
BR
Brazil
Prior art keywords
azt
alone
treatment
combination
nervous system
Prior art date
Application number
BR9611861A
Other languages
English (en)
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BR9611861A publication Critical patent/BR9611861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9611861A 1995-12-05 1996-12-05 Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc BR9611861A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (1)

Publication Number Publication Date
BR9611861A true BR9611861A (pt) 1999-05-18

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611861A BR9611861A (pt) 1995-12-05 1996-12-05 Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc

Country Status (23)

Country Link
US (1) US5646180A (pt)
EP (1) EP0866696B1 (pt)
JP (1) JP2000501713A (pt)
KR (1) KR19990071750A (pt)
CN (1) CN1203530A (pt)
AP (1) AP864A (pt)
AT (1) ATE279922T1 (pt)
AU (1) AU722850B2 (pt)
BR (1) BR9611861A (pt)
CA (1) CA2238471A1 (pt)
CZ (1) CZ291994B6 (pt)
DE (1) DE69633680T2 (pt)
ES (1) ES2231828T3 (pt)
HU (1) HUP9903673A3 (pt)
NO (1) NO317837B1 (pt)
NZ (1) NZ324603A (pt)
OA (1) OA10691A (pt)
PL (1) PL187747B1 (pt)
PT (1) PT866696E (pt)
RU (1) RU2203658C2 (pt)
UA (1) UA61902C2 (pt)
WO (1) WO1997020554A1 (pt)
ZA (1) ZA9610139B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
CZ429398A3 (cs) * 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
AU8017298A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
CA2393466C (en) 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
ES2243556T3 (es) * 2000-10-16 2005-12-01 Conor Medsystems, Inc. Dispositivo medico expandible para proporcionar un agente beneficioso.
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
ATE556706T1 (de) * 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
CA2648891A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3110381B1 (en) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治疗hiv的toll样受体(tlr)调节剂
BR112019012060A2 (pt) 2016-12-14 2020-03-10 Attends Healthcare Products Inc. Laminados absorventes, núcleos absorventes e artigos descartáveis utilizando os laminados absorventes e métodos relacionados
ES3019585T3 (en) 2018-05-28 2025-05-20 Attends Healthcare Products Inc Dryness layer laminate for absorbent articles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
HUP9903673A3 (en) 2000-08-28
US5646180A (en) 1997-07-08
EP0866696B1 (en) 2004-10-20
KR19990071750A (ko) 1999-09-27
PL327061A1 (en) 1998-11-23
CN1203530A (zh) 1998-12-30
PL187747B1 (pl) 2004-09-30
RU2203658C2 (ru) 2003-05-10
CZ170898A3 (cs) 1998-09-16
HUP9903673A2 (hu) 2000-03-28
NO982556L (no) 1998-06-04
AU1148697A (en) 1997-06-27
ES2231828T3 (es) 2005-05-16
AP9801340A0 (en) 1998-09-30
CA2238471A1 (en) 1997-06-12
NO982556D0 (no) 1998-06-04
AP864A (en) 2000-08-11
DE69633680T2 (de) 2006-02-23
ATE279922T1 (de) 2004-11-15
WO1997020554A1 (en) 1997-06-12
AU722850B2 (en) 2000-08-10
JP2000501713A (ja) 2000-02-15
NO317837B1 (no) 2004-12-20
CZ291994B6 (cs) 2003-07-16
ZA9610139B (en) 1997-06-17
NZ324603A (en) 2000-08-25
PT866696E (pt) 2005-03-31
OA10691A (en) 2001-05-04
DE69633680D1 (de) 2004-11-25
UA61902C2 (en) 2003-12-15
EP0866696A1 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
BR9611861A (pt) Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
FI973048A7 (fi) Menetelmät ja koostumukset hydrofiilisten molekyylien lipidisoimiseksi
FR2759581B1 (fr) Dispositif de traitement, notamment par moxa, de type acupressure
PT871619E (pt) Derivados de fenil-tiazol com propriedades anti-virus do herpesc
DK0876205T3 (da) Partikler med polymerkappe samt deres fremstilling
PT978276E (pt) Comprimidos com revestimento de polimero que compreendem amoxicilina e clavulanato
EP0925046A4 (en) TOPICAL PREPARATIONS AND METHODS FOR TREATING HEMORRHOIDS
BR9301371A (pt) Dispositivo de iluminacao e/ou de sinalizacao utilizavel em situacao de neblina
BR9609831A (pt) Composições cosméticas e/ou farmacêuticas antipruríticas
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
FI953717L (fi) 4-Hydroksibentsopyran-2-oneja ja 4-hydroksisykloalkyyli(b)pyran-2-oneja, joita voidaan käyttää retrovirusinfektioiden hoitamiseen
BR9408062A (pt) Tratamento de distúrbios climatéricos com substratos e/ou doadores de óxido nitrico sintase
EE04047B1 (et) Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid
PT93929A (pt) Dispositivo decorativo ou de exibicao para jogos, para divertimento e para finsesteticos
BR9600300A (pt) Artigo e composição aquosa
BR9608309A (pt) Derivados de azacicloalcanos dua preparação e suas aplicações em terapêutica
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
FI940425A7 (fi) Modifioidut oligodeoksiribonukleotidit, niiden valmistus ja niiden terapeuttinen käyttö
FI941814A7 (fi) Alueen suihkujakelulaite ja sen edullinen käyttösovellutus
DE59909860D1 (de) Anwendung von 5'-modifizierten nukleotiden in der molekularbiologie und medizin
PT1030636E (pt) Artigo absorvente com propriedades aperfeicoadas de gestao dos excreta viscosos e fluidos
BR9509925A (pt) Composição e uso da composição para prevenção ou tratamento de infecção por hiv-1
PT96225A (pt) Aquecedor de chumaceiras e similares
NO996496D0 (no) (S) 2-metylamino-2-fenyl-n-butyl 3,4,5-trimetoksybenzoat samt anvendelse av denne ved behandling av kronisk smerte

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]